• Explore /
  • Poster
  • / Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.

Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study.

Abstract Poster

Authors

null

Mingchuan Zhao

Fudan University Shanghai Cancer Center, Shanghai, China

Mingchuan Zhao , Xichun Hu , Aiping Zeng , Yan Yu , Huaqiu Shi , Zhendong Chen , Hongmei Sun , Weihua Yang , Lili Sheng , Peijian Peng , Jingfen Wang , Tienan Yi , Minghong Bi , Mingli Ni , Xiumei Dai , Changlu Hu , Kaijian Lei , Xia Yuan , Qingshan Li , Dongqing Lv

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Clinical Trial Registration Number

NCT04859569

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 12126)

DOI

10.1200/JCO.2023.41.16_suppl.12126

Abstract #

12126

Poster Bd #

494

Abstract Disclosures

Similar Posters

First Author: Zefei Jiang

First Author: Oth Tran

First Author: Alison Stopeck

First Author: Jin Li